Assessing Nanjing Leads Biolabs (SEHK:9887) Valuation After Recent Share Price Volatility

Simply Wall St.05-08

Nanjing Leads Biolabs (SEHK:9887) has drawn fresh attention after recent trading left the stock with a month return of around a 10% decline, even as the past 3 months return stands near 28%. See our ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633450208?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-08 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633450208","market":"sg","top_or_hot":-1,"title":"Assessing Nanjing Leads Biolabs (SEHK:9887) Valuation After Recent Share Price Volatility","media":"Simply Wall St.","content":"<div>\n<p>Nanjing Leads Biolabs (SEHK:9887) has drawn fresh attention after recent trading left the stock with a month return of around a 10% decline, even as the past 3 months return stands near 28%. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/assessing-nanjing-leads-biolabs-sehk9887-valuation-after-rec\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Nanjing Leads Biolabs (SEHK:9887) Valuation After Recent Share Price Volatility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Nanjing Leads Biolabs (SEHK:9887) Valuation After Recent Share Price Volatility\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-08 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/assessing-nanjing-leads-biolabs-sehk9887-valuation-after-rec><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nanjing Leads Biolabs (SEHK:9887) has drawn fresh attention after recent trading left the stock with a month return of around a 10% decline, even as the past 3 months return stands near 28%. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/assessing-nanjing-leads-biolabs-sehk9887-valuation-after-rec\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000500386.USD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/assessing-nanjing-leads-biolabs-sehk9887-valuation-after-rec","article_id":"2633450208","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/assessing-nanjing-leads-biolabs-sehk9887-valuation-after-rec","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2633450208","pubTimestamp":1778244998,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Nanjing Leads Biolabs (SEHK:9887) has drawn fresh attention after recent trading left the stock with a month return of around a 10% decline, even as the past 3 months return stands near 28%.\nSee our latest analysis for Nanjing Leads Biolabs.\nThe latest 1 day share price return of 1.77% and 7 day share price return of 0.75% come after a 59.60% year to date share price gain. The 30 day share price return shows a 10.39% decline, which tempers what still looks like building momentum over the past...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","09887":"维立志博-B","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","BK1161":"生物科技"},"translate_title":"在近期股价波动后评估南京领先生物实验室（SEHK：9887）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"09887":0.9},"content_text":"Nanjing Leads Biolabs (SEHK:9887) has drawn fresh attention after recent trading left the stock with a month return of around a 10% decline, even as the past 3 months return stands near 28%. See our latest analysis for Nanjing Leads Biolabs. The latest 1 day share price return of 1.77% and 7 day share price return of 0.75% come after a 59.60% year to date share price gain. The 30 day share price return shows a 10.39% decline, which tempers what still looks like building momentum over the past 90 days, where the share price return is 28.55%, at a current share price of HK$80.6. If you are weighing this move in context, it can help to see what else is moving and compare with other fast growing ideas through the 125 healthcare AI stocks With Nanjing Leads Biolabs still loss making yet carrying a market cap of HK$15.8b and trading around 18% below analyst price targets, you have to ask whether there is real value here or whether the market is already pricing in future growth. AdvertisementPreferred Price to Book Multiple of 11x: Is it justified? The stock trades on a P/B of 11x, which sits roughly in line with similar peers at 11.2x but far ahead of the wider Hong Kong biotechs industry on 4x. P/B compares a company’s market value with its net assets on the balance sheet. A higher multiple often reflects expectations for future growth or valuable intangible assets that do not fully sit in book value. For Nanjing Leads Biolabs, the 11x P/B suggests investors are already assigning a relatively rich valuation to its clinical stage pipeline and platforms. This is despite the company still reporting a loss of CN¥211.419m on revenue of CN¥177.255m, and the SWS DCF model indicating the HK$80.6 share price is above an estimated future cash flow value of HK$18.54. Compared with the Hong Kong biotechs industry average P/B of 4x, Nanjing Leads Biolabs trades at a clear premium, which points to higher expectations being priced in than for the sector overall. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 11x (OVERVALUED) However, you also have to weigh clinical and regulatory setbacks, or slower than expected progress toward commercialisation, which could challenge the current valuation story. Find out about the key risks to this Nanjing Leads Biolabs narrative. Another View Using Our DCF Model The high 11x P/B suggests a full price, but the SWS DCF model presents a different perspective, with the HK$80.6 share price sitting well above its future cash flow value estimate of HK$18.54, which indicates an overvalued stock on this measure. Which picture do you focus on? Look into how the SWS DCF model arrives at its fair value. 9887 Discounted Cash Flow as at May 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nanjing Leads Biolabs for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 228 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of strong gains and valuation questions leaves you unsure, consider promptly reviewing the full data and forming your own judgment with the 1 key reward and 1 important warning sign Want more ideas before you decide? If you are unsure about focusing only on Nanjing Leads Biolabs, broaden your watchlist with other ideas that match clear, data backed filters on Simply Wall Street. Skip the noise and quickly surface focused opportunities that fit your style using three curated stock lists that many investors overlook until it is too late.  Target potential value opportunities by reviewing stocks that screen well on quality and valuation through the 228 high quality undervalued stocks. Prioritise resilience by checking companies that currently pass strict financial health checks using the solid balance sheet and fundamentals stocks screener (387 results). Get ahead of the crowd by scanning a screener containing 547 high quality undiscovered gems   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Nanjing Leads Biolabs might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633450208","isCrawlerRequest":true}